Our Science

Contract Research

Our CRO business was established in 2022 through the acquisition of Ascent Clinical Research and Applied Biology assets.

This strategic asset purchase transaction involved the purchase of a number of clinical assets, including contracts for clinical trial research with annual revenues of $3 million.

We believe that the valuation was extremely reasonable with the purchase price of $1.3M to date to receive 5% of all future net revenues the assets generate in the combined entity.

The acquisition of the assets of this CRO not only provides Jupiter with immediate revenue, but also positions the company to enter the lucrative clinical research organization market and generate revenues simultaneously along with conducting research on its own products.

Additional contract research opportunities are being pursued at this time. We hope to expand on this line of business in the future.

Email Alerts

News To Your Inbox

For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.